Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03003676
Title A Pilot Study of Sequential ONCOS-102, an Engineered Oncolytic Adenovirus Expressing GMCSF, and Pembrolizumab in Patients With Advanced or Unresectable Melanoma Progressing After Programmed Cell Death Protein 1 (PD1) Blockade
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors Targovax Oy
Indications

melanoma

Therapies

Cyclophosphamide + ONCOS-102 + Pembrolizumab

Age Groups: senior | adult
Covered Countries USA


No variant requirements are available.